Johnson & Johnson $JNJ Stock: Calamos Advisors LLC Raises Position

Calamos Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 656,755 shares of the company's stock after purchasing an additional 9,533 shares during the period. Calamos Advisors LLC's holdings in Johnson & Johnson were worth $173,869,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Joel Adams & Associates Inc. increased its holdings in Johnson & Johnson by 4.3% in the third quarter. Joel Adams & Associates Inc. now owns 2,404 shares of the company's stock worth $637,000 after buying an additional 99 shares during the last quarter. Alta Advisers Ltd grew its stake in Johnson & Johnson by 84.5% in the 3rd quarter. Alta Advisers Ltd now owns 17,284 shares of the company's stock valued at $4,576,000 after buying an additional 7,916 shares during the last quarter. Syverson Strege & Co grew its position in shares of Johnson & Johnson by 2.3% in the third quarter. Syverson Strege & Co now owns 6,445 shares of the company's stock valued at $1,706,000 after purchasing an additional 142 shares during the last quarter. Ullmann Wealth Partners Group LLC increased its position in Johnson & Johnson by 6.5% in the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 13,594 shares of the company's stock worth $3,599,000 after buying an additional 827 shares during the period. Finally, Monte Financial Group LLC boosted its holdings in Johnson & Johnson by 1.9% in the 3rd quarter. Monte Financial Group LLC now owns 34,608 shares of the company's stock valued at $9,162,000 after purchasing an additional 629 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ stock traded up $3.82 during midday trading on Friday, reaching $276.14. 8,859,790 shares of the company's stock traded hands, compared to its average volume of 7,536,766. The company has a 50-day simple moving average of $265.91 and a two-hundred day simple moving average of $248.30. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $185.12 and a 1-year high of $282.02. The company has a market cap of $664.76 billion, a price-to-earnings ratio of 41.84, a PEG ratio of 2.67 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business's quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.16% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on JNJ. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating on the stock in a research note on Thursday, October 15th. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. HSBC boosted their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Royal Bank Of Canada lowered their target price on shares of Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a report on Wednesday, October 14th. Finally, Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.